REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
0.2406 USD   -7.50%
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
06/21Regulus Therapeutics Gets FDA Orphan Designation for RGLS8429
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Still Hanging on for Small Advance

05/11/2022 | 01:46pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BLIRT S.A. 2.05% 14.9 End-of-day quote.75.50%
NASDAQ COMPOSITE 3.34% 11607.62 Real-time Quote.-28.21%
NOVAVAX, INC. -0.27% 51.67 Delayed Quote.-63.88%
QIAGEN N.V. 4.02% 46.63 Delayed Quote.-16.10%
REGULUS THERAPEUTICS INC. -7.50% 0.2406 Delayed Quote.-23.62%
All news about REGULUS THERAPEUTICS INC.
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
PR
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
CI
06/21Regulus Therapeutics Gets FDA Orphan Designation for RGLS8429
DJ
06/13REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/13Regulus Reports First Individual Dosed in Early-Stage Single-Ascending Dose Trial of RG..
MT
06/13Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SA..
PR
06/13Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dos..
CI
06/02Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
PR
05/17Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
PR
05/13REGULUS THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -27,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,23x
Yield 2022 -
Capitalization 35,1 M 35,1 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 11,2x
Nbr of Employees 25
Free-Float 94,7%
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 0,24 $
Average target price 1,50 $
Spread / Average Target 523%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-23.62%35
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574